Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Maria Rosaria Valerio, Alessandro Follador, Jessica Menis, Massimo Di Maio, Giuseppe Luigi Banna, Elena Collovà, Emilio Bria, Silvia Novello

Risultato della ricerca: Articlepeer review


Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen. © 2010 Elsevier Ireland Ltd.
Lingua originaleEnglish
pagine (da-a)78-88
Numero di pagine11
RivistaLung Cancer
Stato di pubblicazionePublished - 2011

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.2700.2740???
  • ???subjectarea.asjc.1300.1306???


Entra nei temi di ricerca di 'Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)'. Insieme formano una fingerprint unica.

Cita questo